The Multiple Sclerosis Treatment Optimization Program
Abstract Objective To design and implement a health system level intervention to reduce escalating multiple sclerosis (MS) disease modifying treatment (DMT) expenditures and improve outcomes. Methods We conducted stakeholder meetings, reviewed pharmacy utilization data, and abstracted information in...
Guardado en:
Autores principales: | Annette Langer‐Gould, Stephen C. Cheng, Bonnie H. Li, Michael H. Kanter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b2d72556b04543fdaace7e951537f3da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Clemens Warnke, et al.
Publicado: (2009) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke C, et al.
Publicado: (2011) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
por: David W Brandes
Publicado: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013) -
Measuring treatment response to advance precision medicine for multiple sclerosis
por: Peter A. Calabresi, et al.
Publicado: (2021)